Where can researchers source third-party tested CJC-1295?

Midwest Peptide supplies research-grade CJC-1295 with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.

Age Verification

You must be 21 years or older to access this website. All products are for research use only.

Are you 21 years of age or older?

By entering, you confirm that you are at least 21 years old and agree to our terms of service.

Memorial Day: 15% off code MEMDAY15Memorial Day Sale — 15% off site-wide with code MEMDAY15

Free shipping on every orderFree shipping on every order

5% off with Zelle or Apple CashSave an extra 5% when you pay with Zelle or Apple Cash

Bulk pricing discounts up to 18%Bulk pricing discounts up to 18% off

CJC-1295 No DAC Research: GHRH Pulse Studies | Midwest Peptide

Ipamorelin Research: Selective GHRP and Ghrelin Receptor Binding StudiesPrev|CJC-1295 and Ipamorelin: A Research Review of Growth Hormone Releasing Peptide CombinationsNext

CJC-1295 No DAC Research: GHRH Analog Pulse Kinetics in Animal Models

CJC-1295 / Ipamorelin · Published April 8, 2026 · Updated May 18, 2026 · 9 min read

Quick Answer

CJC-1295 No DAC is a stabilized GHRH analog studied in research for pulsatile growth hormone release without the extended half-life of the DAC-modified version. Animal model studies examine pulse kinetics, IGF-1 response dynamics, and somatotroph signaling at the pituitary level. For research use only, not for human consumption.

CJC-1295 No DAC Research: GHRH Analog Pulse Kinetics in Animal Models

Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.

What Is CJC-1295 (No DAC)?
GHRH Analog Chemistry
Pulse Kinetics in Animal Research Models
CJC-1295 With DAC vs CJC-1295 No DAC
CJC-1295 No DAC and the GHRH Receptor
CJC-1295 in the CJC/Ipamorelin Blend
Open Research Questions
Conclusion
Related Research Articles
Explore Related Products
Frequently Asked Questions
Glossary

CJC-1295 no DAC research has produced one of the most active areas of preclinical literature on stabilized GHRH analogs and pulse kinetics in growth hormone release studies. As the GHRH analog component of the CJC-1295/Ipamorelin combination, CJC-1295 (no DAC) brings a well characterized mechanism of action and a clean pulse-mimicking profile to research formulations. This article reviews the published literature on CJC-1295 (no DAC), with a focus on its structural features as a stabilized GHRH analog, its pulse kinetics in animal research models, and how the no DAC version differs from the longer acting CJC-1295 with DAC.

Frequently Asked Questions

What is CJC-1295 in research contexts?

CJC-1295 is a synthetic 30-amino-acid analog of growth hormone-releasing hormone (GHRH). It is studied in research models as a long-acting GHRH receptor agonist that drives pulsatile growth hormone release from the pituitary.

How does CJC-1295 no-DAC differ from the DAC-modified form?

CJC-1295 no-DAC retains the four amino acid substitutions for DPP-IV resistance but lacks the maleimidopropionic acid linker that binds serum albumin. As a result, it has a half-life of about 30 minutes, producing discrete GH pulses rather than sustained elevation.

What pulse kinetics are reported with CJC-1295 no-DAC in research?

Animal studies report rapid onset GH release peaking within 30 to 60 minutes after subcutaneous administration, returning to baseline within 4 to 6 hours, more closely mimicking endogenous GHRH pulse architecture than the DAC-modified form.

Is CJC-1295 approved for human use?

No. CJC-1295 is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.

Glossary

Key terms used in this article.

GHRH: Growth hormone-releasing hormone, the hypothalamic peptide that stimulates pituitary growth hormone release.
DAC (Drug Affinity Complex): A maleimidopropionic acid linker on CJC-1295 that covalently binds serum albumin to extend half-life.
Pulsatile Release: The episodic, rhythmic secretion pattern characteristic of growth hormone from the anterior pituitary.
Pituitary Somatotroph: The anterior pituitary cell type that synthesizes and secretes growth hormone.
IGF-1: Insulin-like growth factor 1, the primary downstream mediator of growth hormone action, produced largely in the liver.
Pulse Kinetics: The temporal profile of hormone concentration, including pulse amplitude, frequency, and decay rate.
Modified Tetrasubstituted Sequence: The four amino acid substitutions in CJC-1295 (positions 2, 8, 15, 27) that confer DPP-IV resistance.

More from the Blog

Continue exploring research insights and updates.

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Subcutaneous vs intranasal administration for CNS-targeted research peptides: how to choose between routes for DSIP, Selank, and Kisspeptin based on molecular size, brain access, pharmacokinetics, and the published literature.

May 5, 2026

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

FDA restricted compounded tirzepatide for human use when the shortage ended. The Research Use Only research peptide channel for tirzepatide (GLP-2 TZ) operates under entirely separate regulations.

May 5, 2026

For Research Use Only. CJC-1295 (no DAC) is intended exclusively for in vitro and preclinical research. It is not approved for human use, is not a drug, and should never be administered to humans or to animals outside of a formal research protocol.

What Is CJC-1295 (No DAC)?

CJC-1295 is a tetrasubstituted analog of growth hormone releasing hormone (GHRH), a 44 amino acid neuropeptide that is the primary endogenous regulator of growth hormone release from the anterior pituitary. CJC-1295 retains the active fragment of GHRH (specifically the N-terminal 29 amino acids that constitute the GHRH(1-29) sequence) and incorporates four amino acid substitutions designed to protect the molecule from enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) and other proteases that rapidly clear natural GHRH in research models.

The "no DAC" designation refers to the absence of the drug affinity complex modification that is present in the alternative CJC-1295 with DAC formulation. The DAC modification is a maleimido propionic acid linker that allows CJC-1295 to bind covalently to circulating serum albumin, dramatically extending the functional half life of the peptide in research animals. CJC-1295 with DAC has a half life measured in days, while CJC-1295 (no DAC) has a half life measured in minutes to hours. This difference is the foundation for their distinct research applications.

The stabilizing substitutions in CJC-1295 (no DAC) protect the peptide from proteolytic degradation but do not extend its half life through albumin binding. This makes CJC-1295 (no DAC) functionally similar to a more stable version of natural GHRH, with the practical advantage of being easier to handle in research settings while preserving the pulsatile release pattern that more closely mimics endogenous GHRH activity.

GHRH Analog Chemistry

The chemistry of CJC-1295 (no DAC) builds on decades of research into structure activity relationships in GHRH analogs. Early work on GHRH established that the N-terminal 29 amino acids retained essentially full biological activity, while the C-terminal portion of the natural peptide could be removed without significantly affecting receptor binding. This finding made GHRH(1-29) the foundation for most GHRH analog development, including CJC-1295.

The four amino acid substitutions in CJC-1295 are positioned to protect the peptide from cleavage by DPP-IV and from other proteases that contribute to GHRH degradation in research models. The specific substitutions are designed to preserve the alpha helical structure that is important for GHRH receptor binding while making the peptide resistant to enzymatic clearance. These design choices have been the subject of considerable medicinal chemistry research, and they represent one of the more successful examples of stabilizing a small neuropeptide for research applications.

The result of these modifications is a peptide that retains the receptor binding properties of natural GHRH while having a meaningfully extended functional half life in research models. CJC-1295 (no DAC) is generally described in the published literature as producing GH release with kinetics that approximate a stabilized version of endogenous GHRH pulses, rather than the prolonged tonic elevation produced by the with DAC form.

Pulse Kinetics in Animal Research Models

The pulse kinetics of growth hormone release in research animals have been one of the central topics in CJC-1295 (no DAC) research. Endogenous growth hormone is released in pulsatile bursts under the control of GHRH from the hypothalamus, and the pulsatile nature of this release is functionally important for downstream effects on IGF-1 production and target tissue responses. Research interventions that alter GH pulse patterns have been studied for their effects on the broader somatotropic axis in animal models.

CJC-1295 (no DAC) has been characterized for its effects on GH pulse amplitude, pulse duration, and the overall pattern of GH release in research models. The published findings generally support the use of CJC-1295 (no DAC) as a research tool for studying enhanced but still pulsatile GH release, in contrast to the with DAC form which produces sustained tonic elevation. This distinction is functionally important for research design, since the two forms are appropriate for different experimental questions.

In comparative studies, CJC-1295 (no DAC) has been compared with natural GHRH, with sermorelin (another GHRH(1-29) analog), and with other stabilized GHRH derivatives. The general pattern in the literature is that CJC-1295 (no DAC) produces larger and more sustained GH responses than natural GHRH or sermorelin in research models, while still preserving the pulsatile character of release that distinguishes it from the with DAC form.

CJC-1295 With DAC vs CJC-1295 No DAC

The comparison between CJC-1295 with DAC and CJC-1295 no DAC is one of the more important practical distinctions in the published research literature. Both forms share the same underlying GHRH analog sequence with the same four stabilizing substitutions. The only difference is the presence or absence of the DAC modification, but this single chemical difference produces dramatically different pharmacokinetic profiles in research models.

The with DAC form binds to serum albumin through a thioether linkage formed between the maleimido propionic acid group and a cysteine residue on circulating albumin. This covalent attachment to albumin protects the peptide from clearance and produces a half life measured in days. The result is sustained, tonic GH stimulation in research models, which is appropriate for some research questions but not for others.

The no DAC form lacks the maleimide group entirely and therefore does not form the albumin linkage. Its half life is much shorter, and the resulting GH release pattern is pulsatile rather than tonic. For research questions that require approximation of endogenous GH pulse kinetics, the no DAC form is the appropriate tool. For research questions about sustained tonic stimulation, the with DAC form is more appropriate. The choice between the two depends on the specific experimental design rather than on any inherent superiority of one form over the other.

CJC-1295 No DAC and the GHRH Receptor

CJC-1295 (no DAC) acts as an agonist at the GHRH receptor, a G protein coupled receptor expressed on pituitary somatotroph cells. Activation of this receptor in research models triggers the canonical GHRH signaling cascade, which involves coupling to the Gs alpha subunit, activation of adenylyl cyclase, increases in intracellular cyclic AMP, and downstream activation of protein kinase A. This cascade leads to increased growth hormone gene transcription, GH protein synthesis, and release of stored GH from secretory granules.

The receptor binding properties of CJC-1295 (no DAC) have been characterized in radioligand binding studies and in functional assays of GH release from cultured pituitary cells. The published findings support a similar binding affinity to natural GHRH at the GHRH receptor, with the major functional difference being the resistance to proteolytic clearance rather than any change in the receptor interaction itself.

For more on the alternative pathway that contributes to combined GHRH plus GHRP research, see our companion article on Ipamorelin research and selective GHRP ghrelin receptor binding studies.

CJC-1295 in the CJC/Ipamorelin Blend

In the CJC-1295/Ipamorelin Blend supplied by Midwest Peptide, CJC-1295 (no DAC) provides the GHRH analog component of the formulation. It is paired with Ipamorelin to provide combined activation of both the GHRH receptor and the ghrelin receptor on pituitary somatotroph cells. The pillar article on CJC-1295 and Ipamorelin growth hormone research discusses how the proposed synergy between these two pathways has been studied in research models.

The pulse kinetic profile of CJC-1295 (no DAC) is particularly important for research formulations that combine it with a GHRP. By preserving the pulsatile character of GH release rather than producing tonic elevation, CJC-1295 (no DAC) allows the combined formulation to be used for studies of how enhanced pulses (rather than sustained elevation) affect downstream endpoints in research animals.

For research handling, CJC-1295 (no DAC) is generally well behaved under standard cold storage conditions. Researchers should consult the Certificate of Analysis supplied with the product for peptide identity and purity information.

Open Research Questions

Several open research questions remain in the CJC-1295 (no DAC) literature. These include how the functional half life of the peptide compares quantitatively across different research animal species, how its effects on GH pulse amplitude and frequency depend on dose and route of administration in research models, and how the long term effects of repeated exposure to the peptide differ between the no DAC and with DAC forms in animal studies. Each of these is a legitimate research opportunity for investigators studying the GHRH receptor system.

Conclusion

CJC-1295 (no DAC) research provides a well characterized tool for investigating GHRH-mediated growth hormone release in preclinical models. The stabilizing modifications that protect the peptide from proteolytic clearance, combined with the absence of the DAC modification that would extend half life through albumin binding, produce a research tool with pulse kinetics that approximate enhanced endogenous GHRH activity. Its inclusion in research formulations like the CJC-1295/Ipamorelin Blend reflects an interest in studying combined GHRH plus GHRP signaling at the pituitary level.

For more on the full CJC-1295/Ipamorelin research cluster, see the pillar overview article and the supporting articles on each major topic.

CJC-1295 (no DAC) is supplied by Midwest Peptide for research use only and is not intended for human administration.

Explore more peer-reviewed research and laboratory guides from our science team:

All products are third-party tested with a Certificate of Analysis (COA) included. For research use only.

GHK-Cu 50mg, 99%+ purity, COA included
BPC-157 10mg, 99%+ purity, COA included

Browse All Research Peptides →

Age Verification

CJC-1295 No DAC Research: GHRH Analog Pulse Kinetics in Animal Models

Frequently Asked Questions

What is CJC-1295 in research contexts?

How does CJC-1295 no-DAC differ from the DAC-modified form?

What pulse kinetics are reported with CJC-1295 no-DAC in research?

Is CJC-1295 approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

What Is CJC-1295 (No DAC)?

GHRH Analog Chemistry

Pulse Kinetics in Animal Research Models

CJC-1295 With DAC vs CJC-1295 No DAC

CJC-1295 No DAC and the GHRH Receptor

CJC-1295 in the CJC/Ipamorelin Blend

Open Research Questions

Conclusion

Ready to Start Your Research?

Where can researchers source third-party tested CJC-1295?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?

Age Verification

CJC-1295 No DAC Research: GHRH Analog Pulse Kinetics in Animal Models

Frequently Asked Questions

What is CJC-1295 in research contexts?

How does CJC-1295 no-DAC differ from the DAC-modified form?

What pulse kinetics are reported with CJC-1295 no-DAC in research?

Is CJC-1295 approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

What Is CJC-1295 (No DAC)?

GHRH Analog Chemistry

Pulse Kinetics in Animal Research Models

CJC-1295 With DAC vs CJC-1295 No DAC

CJC-1295 No DAC and the GHRH Receptor

CJC-1295 in the CJC/Ipamorelin Blend

Open Research Questions

Conclusion

Related Research Articles

Explore Related Products

Ready to Start Your Research?

Where can researchers source third-party tested CJC-1295?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?